Malignant hyperthermia: update on susceptibility testing
about
Critical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and DiseasePharmacogenetics and anaesthetic drugs: Implications for perioperative practicePharmGKB summary: very important pharmacogene information for RYR1The human frontal lobes and frontal network systems: an evolutionary, clinical, and treatment perspectiveExome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.Short read (next-generation) sequencing: a tutorial with cardiomyopathy diagnostics as an exemplar.CBF changes associated with focal ischemic preconditioning in the spontaneously hypertensive rat.Anesthetic management of an 8-month-old infant with osteogenesis imperfecta undergoing liver transplantation: a case report.Management of malignant hyperthermia: diagnosis and treatment.CK-MM and ACE genotypes and physiological prediction of the creatine kinase response to exercise.Cerivastatin, genetic variants, and the risk of rhabdomyolysis.Malignant hyperthermia resolving with discontinuation of sevoflurane alone.Special article: Future directions in malignant hyperthermia research and patient careGene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle.Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damageAnesthesia advanced circulatory life support.Serotonin syndrome with paroxetine overdose: a case reportCase files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP.Core myopathies and malignant hyperthermia susceptibility: a review.Exertional heat stroke, rhabdomyolysis and susceptibility to malignant hyperthermia.Undiagnosed myopathy before surgery and safe anaesthesia table.Babies in Distress: Malignant Hyperthermia in Infancy Explored.Malignant hyperthermia, a Scandinavian update.Repeat episodes of severe muscle rigidity in a child receiving sevoflurane.Rhabdomyolysis. The role of diagnostic and prognostic factors.Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.Functional analysis of RYR1 variants linked to malignant hyperthermia.Clinical utility gene card for: malignant hyperthermia.Mind the magnesium, in dantrolene suppression of malignant hyperthermia.Functional and Structural Characterization of a Novel Malignant Hyperthermia-susceptible variant of DHPR-β1a subunit (CACNB1).Sudden death due to malignant hyperthermia with a mutation of RYR1: autopsy, morphology and genetic analysis.Undetected central core disease myopathy in an infant presenting for clubfoot surgery.Heat Stroke
P2860
Q26770423-D4C02FE2-7572-4740-92FD-4A8069C6C087Q26771405-94F31623-26B9-4854-B99A-322984DEC0EFQ28074804-72466446-E117-4879-A235-FC1F7443E9DAQ28709470-476FECB5-CF8B-405B-B713-0ECD9DABFA2DQ30426901-420CF306-D5C9-4AD0-A21D-6433AE171CA9Q30433575-8F84CCC8-A7FD-466F-B55A-7819276DD406Q33231450-6CFE06FE-2C9F-47AB-81E1-9567FDD1AF40Q33857543-6FB9A9EB-F731-4885-95AC-D6722F924D54Q34421643-13FFEEE6-A570-4C5C-A360-5A7F07E8CC62Q34625418-4DEF7882-1288-47A1-8F85-AF24DCA8F50CQ34792178-55D801DC-65DD-4040-8327-85680984DC54Q35114311-CF74BAE2-F156-4E04-9725-1B41A86E105AQ35250678-BAD13235-31A0-4083-B88B-0BACB9B81B85Q35704843-5FBC2FBF-6FB7-434F-916B-408BB98E9D4EQ35787753-E9794684-E6B5-4A47-ACC9-023A0DBD0644Q35936193-C3E1CF9B-C060-4107-A2B8-3F2BC4037066Q36538436-7CEB9A41-7140-4191-A362-4694617981F0Q36549208-9E941A55-651F-41D8-93BE-867B74513F76Q36768338-9884A454-FC1E-4538-BF5A-623A79601A3EQ38101594-85ADBC9E-AAF2-4726-9920-6A62DEBC7E00Q38134154-09E9060D-1943-4E15-89F7-652EFB39C804Q38176599-CE106418-0CC0-475C-A72E-424AE1212277Q38265802-604D4F11-718E-44AB-BC77-1FCA8DCB1A54Q38491486-19FDFD79-E276-4233-8D83-818F27AF285BQ40469925-578D375E-4A62-4B12-AE79-E2190D301B89Q41845560-863A2705-F740-4939-9D30-F39C7D5CC5D0Q41996021-857C52B9-B351-4AE5-81D5-E2D5F7E1CEFFQ42000925-EBC0974A-5000-4870-BA66-599CFE56C4A1Q42748873-D4AEA3C9-B9A4-48F4-9F01-C07B654495C9Q43083643-32612689-0D1E-4FCB-AAE9-46EC8A46E4B0Q46169511-7133A442-0E85-4F13-AAC3-6D854BC369DDQ47235382-6C0AF554-CF8B-459D-8DBB-385B1DC52773Q48614603-9AF0F955-64C9-4CC0-B3A4-1A8F83F9FF3DQ56003963-7806B3B2-AD3B-44CA-95F6-F08BDC386271
P2860
Malignant hyperthermia: update on susceptibility testing
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Malignant hyperthermia: update on susceptibility testing
@ast
Malignant hyperthermia: update on susceptibility testing
@en
Malignant hyperthermia: update on susceptibility testing
@nl
type
label
Malignant hyperthermia: update on susceptibility testing
@ast
Malignant hyperthermia: update on susceptibility testing
@en
Malignant hyperthermia: update on susceptibility testing
@nl
prefLabel
Malignant hyperthermia: update on susceptibility testing
@ast
Malignant hyperthermia: update on susceptibility testing
@en
Malignant hyperthermia: update on susceptibility testing
@nl
P356
P1476
Malignant hyperthermia: update on susceptibility testing
@en
P2093
Henry Rosenberg
Ronald S Litman
P304
P356
10.1001/JAMA.293.23.2918
P407
P577
2005-06-15T00:00:00Z